Dopamine D3 Receptor Mesdopetam Maintains Anti-Dyskinesia Effects Despite Failure to Improve Parkinson Disease ON Time | NeurologyLive – Clinical Neurology News and Neurology Expert Insights
A recent phase 2b study reveals mesdopetam’s potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
January 19, 2026